Telehealth platforms prescribe GLP-1s off-label for addiction before FDA approval
Start here
Telehealth providers are prescribing GLP-1 drugs off-label to treat addiction, moving ahead of any FDA approval for that use. Caron Treatment Centers in Pennsylvania has prescribed the drugs to more than 650 patients with substance use disorders. The approach exploits the gap between the medicines' established safety record in diabetes and obesity and the absence of an approved addiction indication, raising questions about evidence, oversight and access for clinicians and industry watchers. How regulators and payers respond to this fast-moving off-label practice is still open.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- statnews.comPickSTAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Some telehealth platforms are racing ahead of FDA approval by prescribing GLP-1s off-label to patients with addiction. Caron Treatment Centers in Pennsylvania has prescribed these drugs to more than 650 patients with substance use disorders.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 22 17:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.